Combioxin SA announced today that first-in-human clinical results with CAL02 in severe pneumonia patients in ICU will be presented during the ESICM’s annual congress, LIVES 2018, taking place October 20-24, 2018 in Paris, France.
Geneva, Switzerland, 18 October 2018 – Combioxin SA, a clinical-stage biotechnology company focused on the development of innovative treatments for severe and resistant infections, announced today that first-in-human clinical results with CAL02 in severe pneumonia patients in ICU will be presented during the ESICM’s annual congress, LIVES 2018, taking place October 20-24, 2018 in Paris, France.
Presentation details are as follows:
Session: Management of patients with sepsis
Title: Adjunctive intravenous anti-toxin treatment with CAL02 in severe acute community- acquired pneumonia due to Streptococcus pneumoniae. A first-in-man, multicentre, double-blind, placebo-controlled study
Presenter: Pierre-François Laterre, Cliniques universitaires Saint-Luc, Université catholique de Louvain (UCL), Brussels, Belgium
Date: Wednesday, October 24, 2018
Time: 10:10 AM
Location: Barcelona Hall, Palais des Congrès, Paris, France
Presentation number: 0995
The abstract is accessible via the ESICM LIVES 2018 website: http://www.
About CAL02
CAL02 is a novel liposomal agent that acts as a toxin-trap by mimicking microdomains used as cellular docking stations by various bacterial toxins which prompt inflammatory bursts, cause organ damages, favor invasiveness, impede immune defenses, and are also involved in mechanisms of resistance. CAL02 is designed to protect against these deleterious reactions, allowing a faster resolution of organ dysfunction and protecting immune responses. CAL02 is active against toxins produced by major pathogens responsible for common and severe infections including those caused by drug-resistant pathogens.
About Combioxin SA
Combioxin was founded in 2015 and is a Swiss-based clinical-stage biotechnology company committed to the development of innovative anti-infective agents with the potential to transform standard of care. The company is advancing the development its first product, CAL02, for the treatment of severe community-acquired pneumonia and severe hospital-acquired pneumonia. Combioxin is also initiating a program against MDR Gram-negative infections. For more information, please visit http://www.combioxin.com.
Contacts
Combioxin SA
8 rue de la Rôtisserie 1204 Geneva, Switzerland
URL for our press:
http://www.combioxin.com
